Journal of Clinical Oncology
Articles in this Issue
EMB-01, a tetravalent anti-EGFR/cMET bispecific antibody, in the left-sided, RAS/BRAF wild-type, late-line metastatic colorectal cancer: Subgroup analysis of baseline characteristics and response from a phase 1/2 study.
118 Background: Left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC) is sensitive to anti-EGFR containing reg...
Lean individuals with metabolic-dysfunction associated steatotic liver disease and gastrointestinal cancers risk: A retrospective cohort study.
811 Background: Lean individuals with MASLD may represent a distinct subgroup at increased risk for gastrointestinal cance...
Impact of liver-directed therapy on survival in patients with colon cancer and isolated hepatic metastases.
73 Background: Colon cancer with liver-limited metastases represents a subset of patients (pts) with potentially curable d...
Clinical significance of oligometastatic esophageal squamous cell carcinoma: A retrospective cohort study.
391 Background: Oligometastatic disease (OMD) has been proposed as an intermediate state between localized and extensive m...
A phase 1b study to evaluate the safety, tolerability and preliminary efficacy of a heterologous prime boost vaccination (ATP150/ATP152/ATP162, VSV-GP154) and ezabenlimab (BI 754091) in patients with pancreatic ductal adenocarcinoma.
TPS794 Background: Recurrence after resection of pancreatic ductal adenocarcinoma (PDAC) is common, and long-term survival...
Differential neurotoxicity patterns across neuroendocrine tumor grades: A real-world analysis of 12,847 patients.
640 Background: Neuroendocrine tumors (NETs) exhibit substantial heterogeneity across WHO grades, yet treatment-related ne...
Using quantitative pathologic analysis to identify microsatellite stability in digitized colorectal carcinoma images: An effort to screen patients who should be tested for Lynch syndrome.
93 Background: Colorectal cancer (CRC) is the 4th most common cancer among men and women and roughly 2-4% of all CRCs occu...
Preliminary results of benmelstobart (BEN) combined with concurrent chemoradiotherapy (cCRT) versus cCRT alone as neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC): A multicentre, randomised study.
376 Background: While concurrent chemoradiotherapy (cCRT) remains the standard neoadjuvant therapy for resectable esophage...
Characterizing patient attrition across the colorectal cancer screening pathway: Insights from a large, urban direct-access colonoscopy navigation program.
86 Background: Colorectal cancer (CRC) screening can significantly reduce both cancer-related incidence and mortality, yet...
Prediction of chemotherapy-induced peripheral neuropathy using metadata with machine learning models in colorectal cancer patients.
78 Background: Colorectal cancer (CRC) remains a major health burden in Korea. Oxaliplatin is widely used in CRC treatment...
Artificial intelligence (AI) as a decision support tool for practicing oncologists: Gastrointestinal (GI) cancer cases.
854 Background: Multidisciplinary reviews (MDR) are known to alter the management of many cancer patients, yet these resou...
Association of age, stage, and social vulnerability index with colon cancer diagnosis.
37 Background: Colon cancer diagnosed by screening often presents at stage I, offering much higher cure rates than symptom...
An open label phase 2 study of total neoadjuvant therapy (TNT) consisting of FLOT with pembrolizumab and short radiation for patients with locally advanced gastroesophageal junction adenocarcinoma (EPOC2301).
TPS464 Background: Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is the standard of care for r...
Patterns of recurrence in a diverse, population-based sample of adults with early-onset colorectal cancer.
43 Background: The incidence of early-onset colorectal cancer (CRC) among adults under 50 has increased by 22% over the pa...
Circulating tumor DNA to guide rechallenge with cetuximab plus irinotecan in Chinese RAS/BRAF wild type metastatic colorectal cancer: A phase II trial.
154 Background: Standard third-line therapies for metastatic colorectal cancer (mCRC) yield limited clinical benefit. Emer...
Transarterial chemoembolization (TACE) combined with sintilimab and bevacizumab versus TACE alone in patients with Barcelona Clinic Liver Cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis.
506 Background: The efficacy of transarterial chemoembolization (TACE) in Barcelona Clinic Liver Cancer stage B(BCLC-B sta...
Induction FOLFIRINOX and SBRT for borderline/locally advanced pancreatic cancer.
782 Background: FOLFIRINOX is a preferred regimen for borderline and locally advanced pancreatic ductal adenocarcinomas (P...
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in advanced gastric cancer as third-line or later treatment: A multicenter phase II study.
367 Background: Later-line treatment options for advanced gastric cancer (AGC), including nivolumab, irinotecan, and trifl...
Phase 1 dose escalation and expansion study of TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells in combination with cetuximab in patients with colorectal cancer (CRC) with minimal residual disease (MRD).
TPS275 Background: CRC is the second most common cause of cancer-related mortality in the U.S. Despite successful curative...
Trifluridine/tipiracil and pembrolizumab combination as later-line treatment in patients with advanced gastric cancer: A multi-cohort phase II study with lead-in safety cohort (LonKey trial).
389 Background: Despite recent advances in therapeutics, including immune checkpoint inhibitors (ICIs), approved third-lin...
Genomic landscape of homologous recombination deficiency signature in esophageal and gastric adenocarcinomas.
431 Background: Advanced upper gastrointestinal (GI) cancers are aggressive malignancies with poor prognosis, where chemot...
Treatment patterns and outcomes in patients diagnosed with metastatic pancreatic ductal adenocarcinoma (PDAC) and by methylthioadenosine phosphorylase (MTAP) status.
678 Background: PDAC is one of the lead causes of cancer-related mortality in the United States (US)....
Intraperitoneal therapies (IP) for pancreatic ductal adenocarcinoma (PDAC): A systematic synthesis of hyperthermic intraperitoneal chemotherapy (HIPEC), normothermicintraperitoneal chemotherapy, and pressurized intraperitoneal aerosol chemotherapy (PIPAC).
741 Background: IP strategies directly target the peritoneal compartment in PDAC, where systemic chemotherapy alone demons...
Spliceosome-driven transcriptomic profiling to reveal prognostic subtypes and risk stratification in hepatocellular carcinoma.
592 Background: Recent evidence strengthened the link between alterations in spliceosome components and key cellular proce...
Evaluation of early C-reactive protein kinetics as an early response marker in biliary tract cancer patients treated with combined chemoimmunotherapy.
530 Background: Reliable prognostic biomarkers for treatment response in advanced biliary tract cancer (BTC) patients rece...